Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients

Zide Zhang, MMa, Chong Liu, MDa, Tuo Liang, MDa, Chaojie Yu, MDa, Zhaojie Qin, MDa, Xin Zhou, MDa, Jiang Xue, MMa, Haopeng Zeng, MMa, Zhaojun Lu, MMa, Guoyong Xu, MMa, Zequn Wang, MMa, Jiariu Chen, MMa, Jie Jiang, MMa, Xinli Zhan, MDb,

Abstract

Background: In pediatric tumors, immunotherapy exhibits less toxicity than chemotherapy and radiation. The current study aims to identify potential immune targets in immune-related genes of C-C motif chemokine ligand genes (CCLs) and C-C motif chemokine receptors (CCRs) in childhood osteosarcoma (OS) and to explore the underlying molecular mechanisms of childhood OS.

Methods: Firstly, we identified immune-related genes in CCLs and CCRs, these genes were used for functional annotation and interaction analysis. Then, the prognostic value of these genes was evaluated using Kaplan-Meier analysis and multivariate COX regression model. And the potential relationship between risk score and immune infiltrating cells was identified. Finally, gene set enrichment analysis was used to determine the underlying molecular mechanism of OS. Immune-related genes in CCLs and CCRs are inextricably linked.

Results: The results of survival analysis of these genes show that CCL5, CCL8, CCR4, and CCR5 are significantly associated with the prognosis of childhood OS. The combined effect survival analysis shows that the co-high expression of these 4 genes has a good prognosis for childhood OS. A prognostic signature model was constructed based on the 4 genes mentioned above, and the result of time-dependent receiver operating characteristic curves showed that this model was a good predictor of childhood OS 3- and 5-year prognosis. In addition, we found that CCL5, CCL8, and CCR5 may affect the prognosis of OS through complex regulation among Toll-like receptor signaling pathway, mitogen-activated protein kinase (MAPK) family signaling cascade, and nuclear factor-kappaB pathway, whereas CCR4 affects the prognosis of OS by regulating eukaryotic translation.

Conclusion: CCL5, CCL8, CCR4, and CCR5 are potential prognostic markers for the prognosis of childhood OS, and the underlying molecular mechanisms of childhood OS have been identified.

Abbreviations: CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor, GSEA = gene set enrichment analysis, MAPK = mitogen-activated protein kinase, NF-κB = nuclear factor-kappaB, NK = natural killer, OS = osteosarcoma, ROC = receiver operating characteristic, TLR = Toll-like receptor, Tregs = T regulatory cells.

Keywords: C-C motif chemokine ligand genes, C-C motif chemokine receptor, childhood osteosarcoma, immune infiltration, immune prognostic signature, molecular mechanisms

1. Introduction

Osteosarcoma (OS) is the most common solid malignant disease in childhood (an annual incidence of 5.6 cases per million children). OS was rarely diagnosed before age of 5, and the incidence rate reached the peak with age until 10 to 14 years old. The second peak of the age distribution of OS occurred over 50 years old. At present, the treatment of OS is mainly based on resection of primary lesions and combination of multiple...
chemotherapies. The overall survival rate of OS was significantly improved after systematic treatment. However, OS is prone to metastasis in the early stage, and about 30% of patients die of lung metastasis even within 5 years after diagnosis. In addition, drug resistance worsens the prognosis of OS. Therefore, it is essential to identify early diagnostic markers and therapeutic targets for OS. Based on the encouraging results of immunotherapy and gene therapy in OS, the current study aimed to identify new immune targets associated with prognosis.

“Cancer Immunotherapy” was defined as Breakthrough of the Year 2013. The interactions between the immune system and cancer include immune surveillance, immune cell infiltration, and tumor cytology. Immunotherapy counters the immune escape of tumors by targeting the tumor microenvironment and reactivates the patient’s immune system to achieve the goal of recognizing and eliminating tumor cells. In pediatric tumors, immunotherapy exhibits less toxicity than chemotherapy and radiation. The aim of the current study was to identify prognostically relevant immune targets for childhood OS.

A large amount of evidence indicates that C-C motif chemokine ligand genes (CCLs) play an important role in the development, progression, and metastasis of cancers, such as gastric cancer, colorectal cancer, breast cancer, and oral squamous cell carcinoma. C-C motif chemokine receptors (CCRs) are the key mediator of inflammation and immune response, and have significant association with multiple cancers. Nevertheless, the relationship between CCLs, CCRs and the prognosis of childhood OS is still uncertain. Therefore, the aim of the current study was to identify immune-related genes in CCLs and CCRs, and to explore the relationship between these genes and prognosis of childhood OS.

2. Materials and methods

2.1. Gene expression datasets and immune-related genes

The gene expression quantification data of 88 childhood OS samples were of the HTSeq-FPKM type, and downloaded from the University of California, Santa Cruz Xena (UCSC Xena; http://xena.ucsc.edu/) on December 20, 2019. The corresponding clinical data were downloaded from UCSC Xena at the same time. Immune-related genes were downloaded from the Immunology Database and Analysis Portal (ImmPort) database (https://www.import.org/). This study was based on data from an open database. Ethics and patient consent are not applicable.

2.2. Bioinformatics analysis of immune-related genes in CCLs and CCRs

To learn more about the functionality of immune-related genes in CCLs and CCRs, we use the Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/; version 6.8) to perform gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway on these genes. And then, a protein–protein interaction network was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING; https://string-db.org/; version 11) to analyze the correlation between these genes. Finally, a gene-gene interaction network was constructed using GeneMANIA (http://genemania.org/).

2.3. Survival and correlation analysis

According to gene expression level, patients were divided into high- and low-expression group, and then different genes were analyzed for survival (Kaplan-Meier analysis with log-rank test). According to the results, the correlation between genes with significant significance for childhood OS prognosis was analyzed with the Pearson correlation coefficient in R (http://cran.r-project.org/; version 3.6.0) using corplot package. Then the prognosis-related genes were analyzed for combined effect survival (Kaplan-Meier analysis with log-rank test), and a nomogram was constructed. The nomogram was constructed by rms package in R according to the expression of prognosis-related genes.

2.4. Prognostic signature construction

According to the survival analysis results of the above genes, the genes significantly related to the prognosis of childhood OS were combined to construct a prognostic model based on gene expression level. The formula for the risk score was as follows: risk score = (expression value of gene A) \times β_A + (expression value of gene B) \times β_B + \ldots (expression value of gene n) \times β_n; β meant the regression coefficient. In addition, the survival receiver operating characteristic (ROC) package of R software was used to generate time-dependent ROC curves to test the predictive performance of prognostic features.

2.5. Correlation analysis between significant genes expression, risk score, and tumor-infiltrating immune cells

CIBERSORT is a deconvolution algorithm based on gene expression. We downloaded gene expression feature matrix of 22 immune cells from CIBERSORT platform (https://cibersort.stanford.edu/), and then evaluate tumor-infiltrating immune cells of childhood OS samples with CIBERSORT deconvolution algorithm. Finally, the correlation between significant gene expression, risk score of the model, and tumor-infiltrating immune cells was analyzed.

2.6. Gene set enrichment analysis (GSEA)

To further explore the biological pathways of enrichment of these significant survival significance genes, we uploaded the relevant data required for these genes to GSEA (version 4.0.3) and then used the databases of c2 and c5 in the Molecular Signature Database (MSigDB) (https://www.gsea-msigdb.org/) for enrichment analysis. The enrichment gene sets in the GSEA that attained a false discovery rate (FDR) of <0.25 and P < .05 were considered statistical significance.

3. Results

3.1. Data collection and collation

Through careful screening, we obtained 85 OS samples with complete clinical data. Secondly, 34 genes were identified as immune-related genes in CCLs and CCRs. Details of these genes including ID, name, synonyms, chromosome, and category (see Supplementary Table S1, http://links.lww.com/MD/F228, which illustrates the details of immune-related genes in CCLs and CCRs).
Table 1
Enrichment analysis of GO term and KEGG pathway of immune-related genes in CCLs and CCRs.

| Category Term | Count | %  | P-value |
|---------------|-------|----|---------|
| GOTERM_BP_DIRECT GO:0006095--chemokine-mediated signaling pathway | 31 | 1.071923 | <.001 |
| GOTERM_BP_DIRECT GO:0006095--chemotaxis | 29 | 1.002766 | <.001 |
| GOTERM_BP_DIRECT GO:0002548--monocyte chemotaxis | 23 | 0.795297 | <.001 |
| GOTERM_BP_DIRECT GO:0071346--cellular response to interferon-gamma | 23 | 0.795297 | <.001 |
| GOTERM_BP_DIRECT GO:0048247--lymphocyte chemotaxis | 20 | 0.691563 | <.001 |
| GOTERM_BP_DIRECT GO:0071347--cellular response to interleukin-1 | 23 | 0.795297 | <.001 |
| GOTERM_BP_DIRECT GO:0030593--neutrophil chemotaxis | 21 | 0.726141 | <.001 |
| GOTERM_BP_DIRECT GO:0071356--cellular response to tumor necrosis factor | 23 | 0.795297 | <.001 |
| GOTERM_BP_DIRECT GO:0070374--positive regulation of ERK1 and ERK2 cascade | 25 | 0.684454 | <.001 |
| GOTERM_BP_DIRECT GO:0006095--immune response | 22 | 1.002766 | <.001 |
| GOTERM_CC_DIRECT GO:0005615--extracellular space | 25 | 0.684454 | <.001 |
| GOTERM_CC_DIRECT GO:0005576--extracellular region | 20 | 0.691563 | <.001 |
| GOTERM_CC_DIRECT GO:0005623--cell | 9 | 0.311203 | <.001 |
| GOTERM_CC_DIRECT GO:0009897--external side of plasma membrane | 4 | 0.138313 | .00663450 |
| GOTERM_CC_DIRECT GO:0005887--integral component of plasma membrane | 8 | 0.276625 | .01194901 |
| GOTERM_CC_DIRECT GO:0009986--cell surface | 5 | 0.172891 | .01599252 |
| GOTERM_CC_DIRECT GO:0005622--intracellular | 7 | 0.240247 | .0309116 |
| GOTERM_CC_DIRECT GO:0008009--chemokine activity | 25 | 0.864454 | <.001 |
| GOTERM_CC_DIRECT GO:0008020--CCR chemokine receptor binding | 16 | 0.553250 | <.001 |
| GOTERM_CC_DIRECT GO:0001640--C-C chemokine receptor activity | 9 | 0.311203 | <.001 |
| GOTERM_CC_DIRECT GO:0004950--chemokine receptor activity | 7 | 0.240247 | <.001 |
| GOTERM_CC_DIRECT GO:00031726--CCR1 chemokine receptor binding | 5 | 0.172891 | <.001 |
| GOTERM_CC_DIRECT GO:0004279--chemokine receptor binding | 4 | 0.138313 | <.001 |
| GOTERM_CC_DIRECT GO:0004290--chemokine binding | 4 | 0.138313 | <.001 |
| GOTERM_CC_DIRECT GO:00019697--C-C chemokine binding | 3 | 0.103734 | <.001 |
| GOTERM_CC_DIRECT GO:00016004--phospholipase activator activity | 3 | 0.103734 | <.001 |
| GOTERM_CC_DIRECT GO:00031730--C-C chemokine receptor binding | 3 | 0.103734 | <.001 |
| KEGG_PATHWAY hsa04062:Chemokine signaling pathway | 34 | 1.717657 | <.001 |
| KEGG_PATHWAY hsa04060:Cytokine-cytokine receptor interaction | 34 | 1.717657 | <.001 |
| KEGG_PATHWAY hsa05322:Rheumatoid arthritis | 5 | 0.172891 | <.001 |
| KEGG_PATHWAY hsa04672:Intestinal immune network for IgA production | 4 | 0.138313 | .0014276 |
| KEGG_PATHWAY hsa04064:Chemokine signaling pathway | 4 | 0.138313 | .0087077 |
| KEGG_PATHWAY hsa05142:Chagas disease (American trypanosomiasis) | 4 | 0.138313 | .0138232 |
| KEGG_PATHWAY hsa04620:Toll-like receptor signaling pathway | 4 | 0.138313 | .0387510 |

BP = biological process, CC = cellular component, CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor, GO = gene ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes, MF = molecular function.

3.2. Bioinformatics analysis of immune-related genes in CCLs and CCRs

In Table 1 and Figure 1, the results of gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment showed that these genes were enriched in cellular response to tumor necrosis factor, immune response, inflammatory response, positive regulation of T cell migration, mitogen-activated protein kinase (MAPK) cascade, positive regulation of I kappaB kinase (IKK)/ nuclear factor-kappaB (NF-kB) signaling, Toll-like receptor (TLR) signaling pathway and NF-kB signaling pathway (see Supplementary Fig. S1, http://links.lww.com/MD/F222, which shows the map of TLR signaling pathway and see Supplementary Fig. S2, http://links.lww.com/MD/F223, which shows the map of NF-kB signaling pathway). In Figure 2, both STRING and GeneMANIA results showed that these immune-related genes in CCLs and CCRs exhibit close associations, such as shared protein domains, experimentally determined, co-expressed and gene fusions, etc.

3.3. Survival and correlation analysis

Survival analysis showed that CCL5, CCL8, CCR4, and CCR5 were assigned significant statistical significance. High expression of CCL5 (Log-rank $P = .020$), CCL8 (Log-rank $P = .049$), CCR4 (Log-rank $P = .016$) and CCR5 (Log-rank $P = .026$), have better prognosis than low expression. Based on the above 4 genes with significant statistical significance (Table 2 and Fig. 3A–D), Pearson correlation analysis shows that CCL5, CCL8, and CCR4 have a high correlation, while CCR5 has a relatively low correlation with the other 3 genes. The size, number, and color of the circles all represent the correlation between individual genes (Fig. 3E). The combined effect survival analysis of significant genes showed that group C (corresponding genes were at high expression level) had a better prognosis than group A (corresponding genes were at low expression level) and group B (excluding group A and group C, i.e., the expression levels of each gene were not identical). All results are shown in Figure 4. In addition, the results of nomogram also support CCL5, CCL8, CCR4, and CCR5, which were beneficial to the prognosis of childhood OS. The high expression of all genes was at a relatively low point (Fig. 5).

3.4. Construction and validation of prognostic signature based on significant genes

In order to more intuitively show the relationship between the expression of significant genes and prognostic risk, and to
Figure 1. Enrichment analysis of gene ontology term and KEGG pathway of immune-related genes in C-C motif chemokine ligands and C-C motif chemokine receptors. A: biological process. B: cellular component. C: molecular function. D: KEGG pathway. KEGG = Kyoto Encyclopedia of Genes and Genomes.

Figure 2. Gene interactions of immune-related genes in C-C motif chemokine ligands and C-C motif chemokine receptors. A: Search Tool for the Retrieval of Interacting Gene protein-protein association networks. B: GeneMANIA protein-protein association networks.
evaluate the predictive effect, CCL5, CCL8, CCR4, and CCR5 were selected to construct prognostic signatures. The regression coefficients of the four genes in the multivariate COX proportional hazards regression model were CCL5 (−0.579), CCL8 (−0.156), CCR4 (−0.714), and CCR5 (−0.203), respectively. In the current study, the specific formula used to calculate the risk score is as follows: expression of CCL5 × −0.579 + expression of CCL8 × −0.156 + expression of CCR4 × −0.714 + expression of CCR5 × −0.203 + 6 [constant]. Since the regression coefficients are all negative, in order to make the results more intuitive, the constant is used to add to the end of the risk score formula. The results of Kaplan-Meier curves of high- and low-risk groups showed that the high-risk group was significantly associated with poor prognosis of childhood OS, and the difference was statistically significant (Log-rank $P=.024$, Fig. 6B). The time-dependent ROC curve was 0.54, 0.645, and 0.655 for 1-year, 3-year, and 5-year survival, respectively (Fig. 6C).

3.5. Identified potential relationships between significant genes expression, risk score, and tumor-infiltrating immune cells

The results of correlation analysis between the expression of significant genes and tumor-infiltrating immune cells showed that the expression of CCL5, CCL8, CCR4, and CCR5 were all correlated with the level of tumor immune cell infiltration. The expression of CCL5 was significantly correlated with the infiltration levels of macrophages M0, macrophages M1, CD8$^{+}$ T cells and T cells regulatory (Tregs) (see Supplementary Fig. S3, http://links.lww.com/MD/F225, which illustrates the relationships between the expression of CCL5 and tumor-infiltrating immune cells). The expression of CCL8 was significantly correlated with the infiltration levels of macrophages M0, macrophages M1, macrophages M2, neutrophils, resting natural killer (NK) cells, CD8$^{+}$ T cells, and Tregs (see Supplementary Fig. S6, http://links.lww.com/MD/F227, which illustrates the relationships between the expression of CCR5 and tumor-infiltrating immune cells). After successfully constructing the prognostic signature model, we analyzed the correlation between risk score and OS immune infiltration level. The results showed that the risk score was positively correlated with the expression of macrophages M0 ($P<.001$). In addition, the risk score was negatively correlated with the expression of macrophages M1 ($P<.001$), neutrophils ($P=.015$), CD8$^{+}$ T cells ($P<.001$), and Tregs ($P=.001$). The results were shown in Figure 7.

3.6. GSEA

The analysis of c2 and c5 gene sets showed that CCL5 was mainly enriched in TLR signaling pathway, T to NK cells, Parvin-beta, MAPK family signaling cascade, T cell immune response, and NF-$\kappa$B pathway (Fig. 8A–D and see Supplementary Table S2, http://links.lww.com/MD/F229, which shows part of the results of GSEA analysis in the high expression group of CCL5). CCL8 was rich in MAPK family signaling cascade, T to NK cells, NF-$\kappa$B pathway, TLR pathway, production of tumor necrosis factor superfamily cytokines in c2 and c5 gene sets (Fig. 8E–H and see Supplementary Table S3, http://links.lww.com/MD/F230, which shows part of the results of GSEA analysis in the high expression group of CCL5). CCR4 was enriched in eukaryotic translation initiation, eukaryotic translation elongation, ribosome and co-translation protein of target membrane in c2 and c5 gene sets (Fig. 8I–L and see Supplementary Table S4, http://links.lww.com/MD/F231, which shows part of the results of GSEA analysis in the low expression group of CCR4). The results of c2 and c5 gene sets showed that CCR5 was rich in TLR signaling pathway, MAPK family signaling cascade, NIK/NF-$\kappa$B signaling, T to NK cells and chemokine signaling pathway (Fig. 8M–P and see Supplementary Table S5, http://links.lww.com/MD/F232, which shows part of the results of GSEA analysis in the high expression group of CCR5).

4. Discussion

Although immunotherapy has made tremendous progress in adult tumors, less success has been achieved in pediatric tumors. This may be associated with a significant reduction in mutational

---

**Table 2**

| Gene expression level | Patients (n=85) | Number of events | Median survival time (days) | Crude HR (95% CI) | Crude Log-rank $P$-value |
|-----------------------|----------------|-----------------|-----------------------------|------------------|-------------------------|
| CCL5                  |                |                 |                             |                  |                         |
| Low                   | 42             | 18              | 767                         | 1                |                         |
| High                  | 43             | 9               | 1575                        | 0.399 (0.179–0.889) | .020                    |
| CCL8                  |                |                 |                             |                  |                         |
| Low                   | 42             | 18              | 922                         | 1                |                         |
| High                  | 43             | 9               | 1575                        | 0.455 (0.204–1.015) | .049                    |
| CCR4                  |                |                 |                             |                  |                         |
| Low                   | 42             | 18              | 816.5                       | 1                |                         |
| High                  | 43             | 9               | 1625                        | 0.386 (0.173–0.860) | .016                    |
| CCR5                  |                |                 |                             |                  |                         |
| Low                   | 42             | 18              | 816.5                       | 1                |                         |
| High                  | 43             | 9               | 1579                        | 0.411 (0.184–0.920) | .026                    |

CI = confidence interval, HR = hazard ratio, OS = osteosarcoma.
load in childhood cancers leading to a reduction in the number of neoantigens in immunotherapy. However, the relative low toxicity of immunotherapy makes the immunotherapy of pediatric cancer exhibit infinite charm.\textsuperscript{[14,29]} Fortunately, bone biology is inextricably linked to the immune system, which has led to significant implications for immunotherapy of childhood OS.\textsuperscript{[130]} Therefore, many researchers have carried out a large number of studies on OS immunotherapy, such as denosumab.

**Figure 3.** Survival analysis of immune-related genes in CCLs and CCRs and correlation analysis of significant genes. A: CCL5; B: CCL8; C: CCR4; D: CCR5. E: Pearson’s correlation analysis of CCL5, CCL8, CCR4, and CCR5. The size, number, and color of the circles indicate the degree of correlation. CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor.
targeting RANK ligand,[31] adding decitabine to upregulate the expression of cancer antigens,[32] T-VEC and anti-PD-1 antibody pembrolizumab combination test,[33,34] etc. However, in the past 3 decades, progress in improving the prognosis of OS patients has been limited by the failure to identify new active agents or to optimize the use of existing drugs.[32] Therefore, it is necessary to identify potential immune prognostic targets for childhood OS. The purpose of the present study was to identify the relationship between immune-related genes in CCLs, CCRs, and childhood OS patients’ prognosis.
Survival analysis of immune-related genes in CCLs and CCRs showed that high expression of CCL5, CCL8, CCR4, and CCR5 all represented a good prognostic signal for childhood OS. The biological function of CCL5 in tumor is not clear. On the one hand, the production of CCL5 is related to the induction of appropriate immune response to tumor, but on the other hand, CCL5 was related to the progression and metastasis of tumor.[35,36] It was reported that the activation of CCL5 will raise tumor-associated macrophages into tumor microenvironment. Tumor-associated macrophages interact with tumor cells to secrete multiple factors and promote the release of matrix metalloproteinase, thus activating NF-κB signaling pathway to induce epithelial-mesenchymal transition.[37] In addition, CCL5 blocking the selective depletion of Treg cells in tumor microenvironment can promote the anti-tumor immune response of pancreatic ductal adenocarcinoma patients.[38] But we also note that in esophageal squamous cell carcinoma, CCL5 induces CD8 + T cells to infiltrate tumor cells and is associated with better survival.[39] We also found that CCL8 expression leads to the migration of monocytes and T lymphocytes and plays an antitumor role. And CCL8 can directly inhibit the proliferation of tumor cells or transplant tumor cells into tissues.[40] Di Stasi et al found that T lymphocytes coexpressing CCR4 and targeting CD30 chimeric antigen receptor enhance homing and antitumor activity in Hodgkin’s tumor model.[41] In addition, superagonists of CCR5 regulate upstream and downstream events.

![Nomogram constructed based on the expression levels of CCL5, CCL8, CCR4, and CCR5 to predict 1-, 2-, 3-, 4- and 5-year events (mortalities) CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor.](image-url)
Figure 6. Construction and validation of prognostic signature based on the expression levels of CCL5, CCL8, CCR4, and CCR5. A: From top to bottom; risk score plot, survival status scatter plot, and heat map of the expression levels of CCL5, CCL8, CCR4, and CCR5 in high- and low-risk groups. B. Kaplan-Meier curve of high- and low-risk groups. C: The time-dependent ROC curve to validate the ability of the constructed prognostic signature model to predict 1-, 3-, and 5-year survival. CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor, ROC = receiver operating characteristic.

Figure 7. The relationships between risk score and tumor-infiltrating immune cells. A: macrophages M0; B: macrophages M1; C: neutrophils; D:CD8+ T cells; E: Tregs; F: naïve B cells. Tregs, T regulatory cells.
of antitumor responses by participating in adaptive and innate immunity.\textsuperscript{[20,42]} These findings all effectively corroborate our current findings on CCL5, CCL8, CCR4, and CCR5, however, the current findings have limitations because they were obtained from a single cohort and therefore require an external validation cohort to prove the current results.

Tumor-infiltrating immune cells are important for studying the interaction between tumor and immunity, so we explored the correlation between risk score and immune cell infiltration. The results showed that patients with high-risk scores had high levels of macrophages M0 infiltration, whereas patients with low-risk scores had high levels of macrophages M1, neutrophils, CD8\textsuperscript{+} T cells, and Tregs infiltration. Similar to our results, Yang et al found higher levels of macrophages M0 are a high-risk immune subtype for cancer recurrence in the digestive system.\textsuperscript{[43]} Xiong et al found macrophages M1 has antitumor effect in colorectal cancer.\textsuperscript{[44]} Granot et al found that tumor-entrained neutrophils inhibited lung dissemination before transplantation.\textsuperscript{[45]} T cells are an important part of immune cells, which have antitumor effect, especially CD8\textsuperscript{+} and CD4\textsuperscript{+} T cells.\textsuperscript{[46]} Previous studies have found that the presence of Tregs is associated with a positive prognosis in head-and-neck and gastric cancer.\textsuperscript{[47,48]}

Figure 8. The results of GSEA for CCL5 (A–D), CCL8 (E–H), CCR4 (I–L), and CCR5 (M–P) in childhood OS. CCL = C-C motif chemokine ligand, CCR = C-C motif chemokine receptor, GSEA = gene set enrichment analysis, OS = osteosarcoma.
Interestingly, some subtypes of tumor-infiltrating immune cells (such as macrophages M2, B cells, and CD4+ T cells) infiltrate in different tumors, and the difference is given statistical significance, but we did not find any association in the current study, even the subtype infiltration results and our current study results have the opposite situation, which may be related to the difference between different tumors and the functional heterogeneity of immune cell subtypes in tumor progression.

Comprehensive analysis of functional annotations and GSEA results showed that CCL5, CCL8, and CCR5 were significantly enriched in immunity, inflammation, TLR signaling pathway, MAPK family signaling cascade, and NF-κB pathway. The inseparable relationship between immunity, inflammation, and cancer has been widely reported.[49,50] Previous studies have shown that TLRs are negative regulators of cancer and activation of TLRs can lead to activation of MAPKs and NF-κB.[51] However, it has also been found that some TLRs are found in many tumors and produce the effect of tumor cell proliferation and resistance to chemotherapy, but depend on the TLR and tumor type.[52] The role of the NF-κB pathway in cancer is a double-edged sword. On the one hand, the activation of NF-κB can cause immune defense and target transformed cells; on the other hand, NF-κB is constitutively activated in many types of cancer and can play a variety of cancer-promoting roles.[53] Schulze-Osthoff et al found that complex crosstalk mechanisms can be prioritized for experimental studies and needs further prospective study. Finally, the data of the current study come from a single cohort, and the combination analysis sample size is relatively small, which may lead to false-negative results. Secondly, the current study is retrospective and needs further prospective study. Finally, the data of the current study come from a single cohort, and the combination of data from multiple cohorts will make the results more convincing.

Although the current study has some limitations, our study provides a new idea for immunotherapy of childhood OS. We identified immune-related genes in CCLs and CCRs that influence childhood OS progression, and secondly, we identified potential molecular mechanisms that influence childhood OS progression through functional annotation and GSEA. The selected genes and molecular mechanisms can be prioritized for experimental studies to demonstrate their clinical value.

5. Conclusion

CCL5, CCL8, CCR4, and CCR5 are potential biomarkers for the prognosis of childhood OS and have great clinical prospects. In addition, CCL5, CCL8, and CCR5 may affect the prognosis of childhood OS through complex regulation among TLR signaling pathway, MAPK family signaling cascade, and NF-κB pathway, while CCR4 may affect the prognosis of childhood OS by affecting eukaryotic translation.

Acknowledgments

We are grateful to Dr Xinli Zhan (Spine and Osteopathy Ward, The First Affiliated Hospital of Guangxi Medical University,) for his kindly assistance in all stages of the present study.

Author contributions

Conceptualization: Zide Zhang, Tuo Liang, Chaojie Yu, Zhaojie Qin.
Data curation: Zide Zhang, Xin Zhou, Jiang Xue, Haopeng Zeng.
Formal analysis: Zide Zhang.
Funding acquisition: Zide Zhang.
Investigation: Zide Zhang, Zuojun Lu, Guoyong Xu.
Methodology: Zide Zhang, Chong Liu, Xin Zhou.
Project administration: Zide Zhang, Chong Liu, Zequn Wang.
Resources: Zide Zhang.
Software: Zide Zhang, Xinli Zhan.
Supervision: Zide Zhang.
Validation: Zide Zhang, Jiuru Chen, Jie Jiang.
Visualization: Zide Zhang, Chong Liu.
Writing – original draft: Zide Zhang.
Writing – review & editing: Zide Zhang, Xinli Zhan.

References

[1] Hou P, Ji M, Yang B, et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006;106:1602–9.
[2] Anwar MA, El-Baba C, Elnaggar MH, et al. Novel therapeutic strategies for spinal osteosarcomas. Semin Cancer Biol 2020;64:83–92.
[3] Moreno F, Cacciavillano W, Cipolla M, et al. Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. Pediatr Blood Cancer 2017;64:e26533.
[4] Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer 2014;14:722–35.
[5] Wang J, Liu S, Shi J, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm 2019;34:605–13.
[6] Ma C, Nie XG, Wang YL, et al. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Mol Med Rep 2019;19:4205–12.
[7] Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res 2014;162:65–92.
[8] Wu S, Gu Z, Wu Y, et al. LINC00324 accelerates the proliferation and migration of osteosarcoma through regulating WDR66. J Cell Physiol 2020;235:339–48.
[9] Zhang C, Zheng JH, Lin ZH, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY) 2020;12:3486–501.
[10] Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015;33:1688–96.
[11] Wang Y, Yu W, Zhu J, et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 2019;38:168.
[12] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, NY) 2013;342:1432–3.
[13] Schumacher TN, Schreiber RD. Neontogenes in cancer immunotherapy. Science (New York, NY) 2015;348:69–74.
[14] Wedekind MF, Denton NL, Chen CY, et al. Pediatric cancer immunotherapy: opportunities and challenges. Paediatr Drugs 2018;20:395–408.
[15] Wang T, Wei Y, Tian L, et al. C-C motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis. Int J Surg (Lond, Engl) 2016;32:136–42.
[16] Szczepanik AM, Sedlar M, Szaura M, et al. Preoperative serum chemokine (C-C motif) ligand 2 levels and prognosis in colorectal cancer. Pol Arch Med Wewn 2015;125:443–53.

[17] Gao J, Li ZH, Tang W, et al. Chemokine C-C motif ligand 18 expression correlates with tumor malignancy in breast cancer. Pathologie-Biologie 2015;63:199–203.

[18] Lien MY, Tsai HC, Chang AC, et al. Chemokine CCL4 induces vascular endothelial growth factor C expression and lymphangiogenesis by miR-195-3p in oral squamous cell carcinoma. Front Immunol 2018;9:412.

[19] Ryu H, Back SW, Moon JY, et al. C-C motif chemokine receptors in gastric cancer. Mol Clin Oncol 2018;8:3–8.

[20] Zhou X, Liao X, Wang X, et al. Clinical significance and prospective molecular mechanism of C-C motif chemokine receptors in patients with early-stage pancreatic ductal adenocarcinoma after pancreatecoduodenectomy. Oncol Rep 2019;42:1836–68.

[21] Sherman BT, Huang da W, Tan Q, et al. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 2007;8:426.

[22] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 2000;25:25–9.

[23] Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic approaches for pediatric osteosarcoma therapy. Adv Exp Med Biol 2014;804:259–83.

[24] Aldinucci D, Colombatti A. The inflammatory chemokine CCL3 and cancer progression. Mediators Inflamm 2014;2014:292376.

[25] Ge P, Wang W, Li L, et al. Prophylactic vaccination using osteosarcoma cells efficiently induces osteosarcoma cell lysis in vitro. Viruses 2017;9, doi: 10.3390/v9100301.

[26] Schmitz A, Flaherty KT, Patnaik AK, et al. The expression profile of potential osteosarcoma therapy. Adv Exp Med Biol 2014;804:259–83.